Securities Report - 61st Fiscal Period (2025/04/01 - 2026/03/31)

JMS Corporation (hereinafter referred to as "the Company") Securities Report - 61st Fiscal Period (2025/04/01 - 2026/03/31)

This report is a Securities Report submitted by JMS Corporation under the Financial Instruments and Exchange Act, disclosing information on the Company's business performance, financial position, and management policies for the 61st fiscal period (from April 1, 2025 to March 31, 2026).

The Company's primary business involves the development, manufacturing, and sales of medical devices and related products, with particularly strong market share in products related to intravenous therapy and dialysis. This report details the current period's performance overview, consolidated financial statements, Management's Discussion and Analysis (MD&A), future outlook, risk factors, corporate governance status, executive compensation, and matters related to shares.

The Company's management philosophy is "Contributing to medical advancement and safeguarding people's health and safety." Based on this principle, it continues to provide high-quality products that meet medical needs both domestically and internationally. Investment in research and development is ongoing, with new product development focused on home healthcare and elderly medical care progressing steadily.

Regarding financial condition, the Company maintains a stable revenue base and a healthy level of equity ratio. As part of its global expansion strategy, the Company is actively expanding its sales channels in Asian and Western markets. Going forward, it will continue striving for sustainable growth and enhancing shareholder value.